comparemela.com

Latest Breaking News On - Hartmutj ehrlich - Page 9 : comparemela.com

ABX464 s Clinical Benefits for Inflammatory Diseases Revealed in Review

A review study has published the mechanisms and benefits of Abivax's ABX464 to treat inflammatory diseases, including ulcerative colitis.

ABX464 Keeps UC Patients in Remission Over Time, Phase 2 Data Show

ABX464 continues to be effective over time at keeping patients with moderate-to-severe ulcerative colitis in clinical remission, data show.

Abivax Completes Enrollment for Ulcerative Colitis Trial Testing ABX464

Abivax completed patient enrollment ahead of schedule for a trial testing ABX464 for people with moderate to severe ulcerative colitis.

Abivax publishes novel data with respect to obefazimod s anti-inflammatory mechanism of action

EQS-News: ABIVAX / Key word(s): Scientific publicationAbivax publishes novel data with respect to obefazimod’s anti-inflammatory mechanism of action 05.01.2023 / 08:00 CET/CESTThe issuer is solely responsible for the content of this announcement.Abivax publishes novel data with respect to obefazimod’s anti-inflammat.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.